Drug Shows Promise for Genetic Proopiomelanocortin Deficiency

Share this content:
Drug Shows Promise for Genetic Proopiomelanocortin Deficiency
Drug Shows Promise for Genetic Proopiomelanocortin Deficiency

THURSDAY, July 21, 2016 (HealthDay News) -- An experimental drug spurred substantial weight loss in patients with proopiomelanocortin (POMC) deficiency, according to a study published in the July 21 issue of the New England Journal of Medicine.

In the new study, researchers in France and Germany tested an experimental compound called setmelanotide in two adults with POMC deficiency. The drug is being developed by a Boston biotech firm called Rhythm Pharmaceuticals, to treat rare genetic causes of obesity. According to the company, setmelanotide activates a receptor on cells that would normally be turned on by melanocyte-stimulating hormone, derived from POMC.

The patients in this study -- both women in their 20s -- were severely obese, weighing close to 350 pounds. After about 10 months of daily setmelanotide injections, one patient had lost 112 pounds. The other lost 45 pounds over three months of treatment. The first patient initially had her treatment stopped after three months. She immediately became excessively hungry and began to regain the weight, lead researcher Peter Kuhnen, M.D., of the Charite-Medical University of Berlin, told HealthDay. Once the patient went back on the drug, her hunger eased and her weight loss continued.

"For this reason, we presume that the patients will need to take the drug indefinitely," Kuhnen said.

One author disclosed financial ties to Rhythm Pharmaceuticals, which provided the study medication and regulatory support.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Nocturia May Be Reduced by Cutting Daily Intake of Salt

Nocturia May Be Reduced by Cutting Daily Intake ...

An easy way for patients to reduce nighttime urination and subsequent impact on sleep

Smoking Ups Long-Term Risks From Radiotherapy in Breast CA

Smoking Ups Long-Term Risks From Radiotherapy in Breast ...

Risk associated with radiotherapy for breast cancer is substantially reduced with smoking cessation

Impact of Breastfeeding on Child Development May Be Short-Lived

Impact of Breastfeeding on Child Development May Be ...

After propensity matching, only statistically significant outcome was hyperactivity at age 3 years

is free, fast, and customized just for you!

Already a member?

Sign In Now »